Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognitive impairment patients on v-3 supplementation

FASEB Journal

Volumn 31, Issue 1, 2017, Pages 148-160

  Famenini, Sam ^a   Rigali, Elizabeth A ^a   Olivera Perez, Henry M ^a   Dang, Johnny ^a   Chang, Michael To ^a   Halder, Ramesh ^a   Rao, Rammohan V ^b   Pellegrini, Matteo ^a   Porter, Verna ^c,d   Bredesen, Dale ^b,c,d   Fiala, Milan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^c Department of Neurology ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyloid b phagocytosis; Apoe genotype; Inflammation; Resolvin D1; 3 fatty acids

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANTIOXIDANT; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; B7 ANTIGEN; CD163 ANTIGEN; CD206 ANTIGEN; COLECALCIFEROL; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; OMEGA 3 FATTY ACID; PRASTERONE; PROTEIN; RECEPTOR; RESOLVIN; RESVERATROL; SMARTFISH AS; TESTOSTERONE; UNCLASSIFIED DRUG; APOLIPOPROTEIN E;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMNESIA; ARTICLE; CLINICAL ARTICLE; COGNITION; DEMENTIA; DEPRESSION; DIET SUPPLEMENTATION; DOWN REGULATION; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; PHAGOCYTOSIS; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; UPREGULATION; VERY ELDERLY; BLOOD; CLASSIFICATION; COGNITION DISORDERS; DIETARY SUPPLEMENT; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

AGED; AGED, 80 AND OVER; APOLIPOPROTEINS E; COGNITION; COGNITION DISORDERS; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MACROPHAGES; MALE; MIDDLE AGED;

EID: 85009804001     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.201600677RR     Document Type: Article

References (42)

1. McGeer, P. L., and McGeer, E. G. (2015) Targeting microglia for the treatment of Alzheimer's disease. Expert Opin. Ther. Targets 19, 497-506.
2. Fiala, M., Liu, P. T., Espinosa-Jeffrey, A., Rosenthal, M. J., Bernard, G., Ringman, J. M., Sayre, J., Zhang, L., Zaghi, J., Dejbakhsh, S., Chiang, B., Hui, J., Mahanian, M., Baghaee, A., Hong, P., and Cashman, J. (2007) Innate immunity and transcription of MGATIII and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc. Natl. Acad. Sci. USA 104, 12849-12854.
3. Fiala, M., Halder, R. C., Sagong, B., Ross, O., Sayre, J., Porter, V., and Bredesen, D. E. (2015) v-3 Supplementation increases amyloid-b phagocytosis and resolvin D1 in patients with minor cognitive impairment. FASEB J. 29, 2681-2689.
4. Mrak, R. E., and Griffin, W. S. (2001) Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol. Aging 22, 903-908.
5. McGeer, P. L., Akiyama, H., Itagaki, S., and McGeer, E. G. (1989) Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107, 341-346.
6. Rogers, J., Schultz, J., Brachova, L., Lue, L. F., Webster, S., Bradt, B., Cooper, N. R., and Moss, D. E. (1992) Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease. Res. Immunol. 143, 624-630.
7. Fiala, M., Liu, Q. N., Sayre, J., Pop, V., Brahmandam, V., Graves, M. C., and Vinters, H. V. (2002) Cyclooxygenase-2- positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Eur. J. Clin. Invest. 32, 360-371.
8. Hardy, J., and Selkoe, D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
9. ElAli, A., and Rivest, S. (2016) Microglia in Alzheimer's disease: a multifaceted relationship. Brain Behav. Immun. 55, 138-150.
10. Zaghi, J., Goldenson, B., Inayathullah, M., Lossinsky, A. S., Masoumi, A., Avagyan, H., Mahanian, M., Bernas, M., Weinand, M., Rosenthal, M. J., Espinosa-Jeffrey, A., de Vellis, J., Teplow, D. B., and Fiala, M. (2009) Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. Acta Neuropathol. 117, 111-124.
11. Mizwicki, M. T., Liu, G., Fiala, M., Magpantay, L., Sayre, J., Siani, A., Mahanian, M., Weitzman, R., Hayden, E. Y., Rosenthal, M. J., Nemere, I., Ringman, J., and Teplow, D.B. (2013) 1a, 25-Dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-b phagocytosis and inflammation in Alzheimer's disease patients. J. Alzheimers Dis. 34, 155-170.
12. Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., Geny, B., Laakso, M., Puigserver, P., and Auwerx, J. (2006) Resveratrol improvesmitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127, 1109-1122.
13. Liu, C. C., Kanekiyo, T., Xu, H., and Bu, G. (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106-118.
14. Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., Goate, A.M., Bales, K.R., Paul, S.M., Bateman, R. J., and Holtzman, D. M. (2011)Human apoE isoforms differentially regulate brain amyloid-b peptide clearance. Sci. Transl. Med. 3, 89ra57.
15. Theendakara, V., Peters-Libeu, C. A., Spilman, P., Poksay, K. S., Bredesen, D.E., and Rao, R. V. (2016)Direct transcriptional effects of apolipoprotein E. J. Neurosci. 36, 685-700.
16. Theendakara, V., Patent, A., Peters Libeu, C. A., Philpot, B., Flores, S., Descamps, O., Poksay, K. S., Zhang, Q., Cailing, G., Hart, M., John, V., Rao, R. V., and Bredesen, D. E. (2013) Neuroprotective Sirtuin ratio reversed by ApoE4. Proc. Natl. Acad. Sci. USA 110, 18303-18308.
17. Salem, N. Jr., Vandal, M., and Calon, F. (2015) The benefit of docosahexaenoic acid for the adult brain in aging and dementia. Prostaglandins Leukot. Essent. Fatty Acids 92, 15-22.
18. Calder, P. C. (2015) Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim. Biophys. Acta 1851, 469-484.
19. Morris, M. C., Brockman, J., Schneider, J. A., Wang, Y., Bennett, D. A., Tangney, C. C., and van de Rest, O. (2016) Association of seafood consumption, brain mercury level, and APOE e4 status with brain neuropathology in older adults. JAMA 315, 489-497.
20. Jicha, G. A., and Markesbery, W. R. (2010) Omega-3 fatty acids: potential role in the management of early Alzheimer's disease. Clin. Interv. Aging 5, 45-61.
21. Cederholm, T., Salem, N. Jr., and Palmblad, J. (2013) v-3 fatty acids in the prevention of cognitive decline in humans. Adv. Nutr. 4, 672-676.
22. Annweiler, C., Llewellyn, D. J., and Beauchet, O. (2013) Low serum vitamin D concentrations in Alzheimer's disease: a systematic review and meta-analysis. J. Alzheimers Dis. 33, 659-674.
23. Huang, T. L., Zandi, P. P., Tucker, K. L., Fitzpatrick, A. L., Kuller, L.H., Fried, L. P., Burke, G. L., and Carlson, M. C. (2005)Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 65, 1409-1414.
24. Freund-Levi, Y., Eriksdotter-J onhagen, M., Cederholm, T., Basun, H., Faxen-Irving, G., Garlind, A., Vedin, I., Vessby, B., Wahlund, L. O., and Palmblad, J. (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol. 63, 1402-1408.
25. Serhan, C. N. (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92-101.
26. Fiala, M., Terrando, N., and Dalli, J. (2015) Specialized pro-resolving mediators from omega-3 fatty acids improve amyloid-b phagocytosis and regulate inflammation in patients with minor cognitive impairment. J. Alzheimers Dis. 48, 293-301.
27. Bredesen, D. E. (2014) Reversal of cognitive decline: a novel therapeutic program. Aging (Albany, N.Y.) 6, 707-717.
28. Bredesen, D.E., Amos, E.C., Canick, J., Ackerley, M., Raji, C., Fiala, M., and Ahdidan, J. (2016) Reversal of cognitive decline in Alzheimer's disease. Aging (Albany, N.Y.) 8, 1250-1258.
29. Serhan, C. N., Chiang, N., and Dalli, J. (2015) The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin. Immunol. 27, 200-215.
30. Serhan, C. N., and Petasis, N. A. (2011) Resolvins and protectins in inflammation resolution. Chem. Rev. 111, 5922-5943.
31. Serhan, C. N., Krishnamoorthy, S., Recchiuti, A., and Chiang, N. (2011) Novel anti-inflammatory-pro-resolving mediators and their receptors. Curr. Top. Med. Chem. 11, 629-647.
32. Li, L., Wu, Y., Wang, Y., Wu, J., Song, L., Xian, W., Yuan, S., Pei, L., andShang, Y. (2014) Resolvin D1 promotes the interleukin-4-induced alternative activation in BV-2 microglial cells. J. Neuroinflammation 11, 72.
33. Sica, A., and Mantovani, A. (2012) Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787-795.
34. Schif-Zuck, S., Gross, N., Assi, S., Rostoker, R., Serhan, C. N., and Ariel, A. (2011) Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. Eur. J. Immunol. 41, 366-379.
35. Girodet, P. O., Nguyen, D., Mancini, J. D., Hundal, M., Zhou, X., Israel, E., and Cernadas, M. (2016) Alternativemacrophage activation is increased in asthma [E-pub ahead of print]. Am. J. Respir. Cell Mol. Biol. doi:0.1165/rcmb.2015-0295OC.
36. Croasdell, A., Thatcher, T. H., Kottmann, R.M., Colas, R. A., Dalli, J., Serhan, C.N., Sime, P. J., and Phipps, R. P. (2015)Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 309, L888-L901.
37. Xue, J., Schmidt, S. V., Sander, J., Draffehn, A., Krebs, W., Quester, I., De Nardo, D., Gohel, T. D., Emde, M., Schmidleithner, L., Ganesan, H., Nino-Castro, A., Mallmann, M. R., Labzin, L., Theis, H., Kraut, M., Beyer, M., Latz, E., Freeman, T. C., Ulas, T., and Schultze, J. L. (2014) Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40, 274-288.
38. Raine, A., Portnoy, J., Liu, J., Mahoomed, T., and Hibbeln, J. R. (2015) Reduction in behavior problems with omega-3 supplementation in children aged 8-16 years: a randomized, double-blind, placebocontrolled, stratified, parallel-group trial. J. Child Psychol. Psychiatry 56, 509-520.
39. Mizwicki, M. T., Menegaz, D., Zhang, J., Barrientos-Duŕan, A., Tse, S., Cashman, J. R., Griffin, P. R., and Fiala, M. (2012) Genomic and nongenomic signaling induced by 1a, 25(OH)2-vitamin D3 promotes the recovery of amyloid-b phagocytosis by Alzheimer's diseasemacrophages. J. Alzheimers Dis. 29, 51-62.
40. Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., and Winblad, B. (2001) Current concepts in mild cognitive impairment. Arch. Neurol. 58, 1985-1992.
41. Duara, R., Loewenstein, D.A., Greig, M.T., Potter, E., Barker, W., Raj, A., Schinka, J., Borenstein, A., Schoenberg, M., Wu, Y., Banko, J., and Potter, H. (2011) Pre-MCI andMCI:neuropsychological, clinical, and imaging features and progression rates. Am. J. Geriatr. Psychiatry 19, 951-960.
42. Jofre-Monseny, L., Loboda, A., Wagner, A. E., Huebbe, P., Boesch-Saadatmandi, C., Jozkowicz, A., Minihane, A. M., Dulak, J., and Rimbach, G. (2007) Effects of apoE genotype on macrophage inflammation and heme oxygenase-1 expression. Biochem. Biophys. Res. Commun. 357, 319-324.